Project Grant 2604339
Award Date 10/1/26
Completion Date 9/30/27
Dollars Obligated $305K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Logan, UT, USA
Similar Awards
- The National Eye Institute awarded Synvivo Inc. $290,400 on September 15, 2026, under the Vision Research program (CFDA 93.867) to develop the first standardized, commercial retinal barrier-on-chip using donor-matched human primary retinal pigment epithelial and choroidal endothelial cells for age-related macular degeneration (AMD) therapeutic testing. Synvivo will design and fabricate a retinal barrier-on-chip in a 3-plex array configuration integrating human choroidal endothelial cells...
- The National Eye Institute awarded The Leland Stanford Junior University $666,976 on August 1, 2026, under the Vision Research program (CFDA 93.867) to map age-related macular degeneration (AMD) using precision proteomics and molecular aging analysis. The recipient will deploy the TEMPO (Tracing Expression of Multiple Protein Origins) platform to profile protein biomarkers and identify cellular drivers of AMD in living patients using human liquid biopsy samples. TEMPO integrates aptamer-based...
- Federal Grant Award Summary Glaive Medical Optics Inc. received a $304,998 Small Business Innovation Research (SBIR) Phase I award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) on October 1, 2025, with completion targeted for September 30, 2026. The awardee will develop a novel implantable intraocular lens device incorporating a low-power, rechargeable visible-light phase shifter and optical phased arrays designed to...
- The National Eye Institute awarded Cleveland Clinic Lerner College of Medicine of Case Western Reserve University $615,928 on April 15, 2026, under the Vision Research program (CFDA 93.867) to investigate the mechanobiology of Bruch's membrane during aging and its implications for age-related retinal degenerations. The project will map the spatial and temporal matrisome—the complete set of extracellular matrix proteins—of the retinal pigment epithelium, Bruch's membrane, and choriocapillaris...
- The National Science Foundation Division of Chemical, Bioengineering, Environmental, and Transport Systems awarded the University of Utah $500,106 on July 1, 2026, for development of a high-fidelity cornea-on-a-chip device under the Engineering program (CFDA 47.041). The award funds creation of a physiologically accurate, miniature in vitro platform that mimics the structure and function of the human cornea for ocular drug evaluation and disease study. The cornea chip will contain the three main...
- The National Science Foundation awarded Macula Vision Systems Inc. a $1.249 million cooperative agreement on August 1, 2026, under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop and validate an automated gram stain interpretation platform using digital holographic microscopy and artificial intelligence. The project will build on Phase I proof-of-concept results to create a compact, cost-effective imaging system capable of high-throughput, full-slide scanning...
- The National Science Foundation awarded Lightfinder Inc. $1,247,250 in a Cooperative Agreement on August 1, 2026, under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop chip-scale optical coherence tomography (OCT) imaging technology for pathology applications. The Phase II Small Business Innovation Research project integrates photonic interferometry, beam steering, and detection into a single silicon chip using scalable CMOS-compatible manufacturing methods. The...
- The National Eye Institute awarded The Methodist Hospital Research Institute $1,029,472 on May 1, 2026, under the Vision Research program (CFDA 93.867) to develop mitochondrial-based cell therapy for age-related macular degeneration. The recipient will create a sustainable source of mitochondria proximal to the retinal pigment epithelium using mesenchymal stem cells transfected with nuclear respiratory factor 1 (NRF1), a driver of mitochondrial biogenesis. The work aims to determine how NRF1...
- The National Eye Institute awarded the University of Rochester a $2,215,463 cooperative agreement on March 17, 2026, under the Vision Research program (CFDA 93.867) to develop small molecule PROTAC compounds targeting secretory phospholipase A2-IIA (SPLA2-IIA) for treatment of age-related macular degeneration and related macular dystrophies. The award funds development of proteolysis-targeting chimera compounds designed to induce degradation of SPLA2-IIA, a pro-inflammatory enzyme identified...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Macula Vision Systems Inc., a for-profit organization, supports the development of a novel microscopy platform to automate the interpretation of microbiology lab tests performed in hospitals. The project aims to address the shortage of trained lab technicians by engineering a specialized light source, customized camera, and AI-enabled algorithms to analyze...